thalidomide has been researched along with Adrenal Insufficiency in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Adrenal Insufficiency: Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The major adverse events (AEs) associated with lenalidomide include: hematological toxicities (myelosuppression), mainly neutropenia, venous thromboembolism, gastrointestinal disturbance, skin toxicity, atrial fibrillation, asthenia, and decreased peripheral blood stem cell yield during stem cell collection when lenalidomide is used after a long period of time." | 5.37 | Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. ( García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E, 2011) |
| " The major adverse events (AEs) associated with lenalidomide include: hematological toxicities (myelosuppression), mainly neutropenia, venous thromboembolism, gastrointestinal disturbance, skin toxicity, atrial fibrillation, asthenia, and decreased peripheral blood stem cell yield during stem cell collection when lenalidomide is used after a long period of time." | 1.37 | Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. ( García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pérez Persona, E | 1 |
| Mesa, MG | 1 |
| García Sánchez, PJ | 1 |
| González Rodríguez, AP | 1 |
1 other study available for thalidomide and Adrenal Insufficiency
| Article | Year |
|---|---|
Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.
Topics: Adrenal Insufficiency; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2011 |